Astrazeneca Pharma Q1 results show revenue up from 282.70 crores to 303.57 crores, a 7.38% increase in growth. EPS rise from ₹6.91 to ₹21.54, up by 211.72%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Astrazeneca Pharma shared its Q1 results on Monday. They earned 303.57 crores in revenue this quarter, but that’s more than the 282.70 crores they made last quarter. The company’s growth increased by 7.38 percent when comparing the two quarters.
In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 53.86 crores, up from 17.27 crores in the previous quarter. Their quarter-to-quarter growth increased by 211.85 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹21.54, which is an increase of 211.72% from the ₹6.91 EPS in the previous quarter.
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 303.57 crores this year (2023), which is 28.39 percent higher than last year’s total revenue of 236.44 crores.
This year’s PAT (Profit After Tax) is 53.8607 crores, which is also 167.26% higher than last year’s PAT of 20.15 crores.
The EPS (Earnings Per Share) for this year is ₹21.54, which is 167.25% more than the EPS of ₹8.06 earned last year.
Also Read: Grindwell Norton Q1FY24 Results: Consolidated PAT Down to Rs. 96.99 Cr
Astrazeneca Pharma Share Dividend Announcement / Record Date:
The record date for the dividend has not arrived yet.
About Astrazeneca Pharma:
AstraZeneca plc stands as a multinational pharmaceutical and biotechnology company, hailing from both British and Swedish origins. The company’s headquarters are situated at the Cambridge Biomedical Campus in Cambridge, England, as per information from Wikipedia.
Download the Full PDF of Astrazeneca Pharma Q1 Results: Click Here
For more of the Latest News, Click Here
